(MENAFN- Trend News Agency) Saliravira, a medicament developed by Iranian scientists and
produced by MIM Daroo Pharmaceutical Company, has succeeded in
getting international patent certificate in terms of reducing
effects of COVID-19, trend reports citing irna .
Reza Ramezani, director general of the MIM Daroo Pharmaceutical
Company, said on Sunday that the medicine was registered in Iran in
last year and the healthcare officials in the country issued legal
permissions for the usage of the medicament at national level.
To this end, preclinical and clinical examinations were carried
out, he said, noting that Iran University of Medical Sciences,
which is a branch of the World Intellectual Property Organization
in the country, issued code of ethics and clinical trial before the
examinations, he said.
The pharmaceutical company signed a contract with a valid
European firm to pave the way for achieving international patent
certificate, Ramezani added.
According to Iran's Vice Presidency for Science and Technology,
over 40 researchers from the best universities of the country were
involved in the study to develop Saliravira.
Saliravira as the first Iran-made medicament to treat
coronavirus was unveiled for the first time in Tehran on June 7,
2021.
Saliravira has the potential to act as an antiviral agent,
accelerate treatment, reduce undesirable effects of COVID-19, and
enhance immunity for treatment of the disease.
Saliravira is a natural medicine; composed of Echinacea
purpurea, Glycyrrhiza glabra, Rheum palmatum, Hyssopus officinalis,
Rosmarinus officinalis, and Panax ginseng.
Toxicity studies on mice did not show significant difference
between control and intervention groups.
Clinical trial results indicated, viral loads of the patients in
the intervention group on the 8th day after the start of treatment
was significantly lower in comparison to the control group.
MENAFN25122022000187011040ID1105351851
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.